Trial Profile
Phase I Trial of ZW25 in Patients With Locally Advanced (Unresectable) and/or Metastatic HER2-expressing Cancers
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 19 Dec 2023
Price :
$35
*
At a glance
- Drugs Zanidatamab (Primary) ; Capecitabine; Paclitaxel; Tucatinib; Vinorelbine
- Indications Adenocarcinoma; Advanced breast cancer; Biliary cancer; Cervical cancer; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Gallbladder cancer; Gastric cancer; Gastrointestinal cancer; Gynaecological cancer; HER2 positive breast cancer; Male breast cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Parotid cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Zymeworks
- 11 Aug 2023 Planned End Date changed from 1 Aug 2023 to 1 Jul 2024.
- 11 Aug 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2024.
- 19 Apr 2023 Results assessing to detect ERBB2 amplification in plasma samples in ctDNA as a surrogate for tumor tissue FISH analysis of HER2 status in a phase 1 study with zanidatamab in multiple cancer types, presented at the 114th Annual Meeting of the American Association for Cancer Research.